FDMT
4D Molecular Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$530.08M
P/E Ratio
—
EPS
$-2.57
Beta
2.76
52W High
$12.34
52W Low
$3.02
50-Day MA
$9.37
200-Day MA
$8.79
Dividend Yield
—
Profit Margin
-182.30%
Forward P/E
—
PEG Ratio
—
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Fundamentals
| Revenue (TTM) | $88.24M |
| Gross Profit (TTM) | $-128.53M |
| EBITDA | $-171.43M |
| Operating Margin | -2416.00% |
| Return on Equity | -34.90% |
| Return on Assets | -21.40% |
| Revenue/Share (TTM) | $1.45 |
| Book Value | $8.64 |
| Price-to-Book | 1.17 |
| Price-to-Sales (TTM) | 6.01 |
| EV/Revenue | 1.816 |
| EV/EBITDA | -3.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 21664.00% |
| Shares Outstanding | $52.28M |
| Float | $36.49M |
| % Insiders | 3.54% |
| % Institutions | 104.88% |
Historical Volatility
HV 10-Day
63.83%
HV 20-Day
55.67%
HV 30-Day
68.60%
HV 60-Day
64.37%
HV Rank
9.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.22 target)
2
Strong Buy7
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/11/2026